[ad_1]
After two successful vaccination trials, the Center decided to launch the national vaccination campaign on January 16 after upcoming festivals such as Lohri, Makar Sankranti, Pongal, Magh Bihu, etc., government sources said on Saturday. The decision came after the Prime Minister chaired a high-level review meeting with the Secretary to the Cabinet, the Prime Minister’s Principal Secretary, the Health Secretary and other senior officials to review the status of COVID- 19 in the country as well as State / UT readiness. for COVID vaccination. The Prime Minister will interact with all MCs on Monday in much the same way.
Army takes Chinese soldier into custody after passing through Indian side of LAC
Vaccine deployment on January 16
Priority will be given to health workers and frontline workers, estimated to number around 3 crore, who are currently registered on the government’s CO-Win app – 75 lakh beneficiaries already registered. Next in line are people over 50 and population groups under 50 with co-morbidities of around 27 crore will be vaccinated by July. More than 61,000 program managers, 2 lakh vaccinators and 3.7 lakh other members of the immunization team have been trained so far through trainings at state, district and block levels. The government has not yet placed an official order with the maker of COVISHIELD – Serum Institute of India (SII), which has stored 50 million doses for India.
Dry vaccine trials
With India’s COVID-19 tally affecting 1.04,31,639 cases and active cases dropping to 2,24,190, the country has kept its vaccine dry in 700 districts in all states / UTs of India, except Uttar Pradesh and Haryana on January 8. the previous vaccination trial, 286 session sites in 125 districts took place on January 2. Both trials were successful and aimed to ensure effective planning and management of vaccine distribution in all states and areas of the Union, with Union Minister of Health Dr Harsh Vardhan moving on to reviewed the dry run in Chennai earlier today.
PM Modi to chair all MCs meeting on January 11 to discuss COVID-19 vaccine deployment
DCGI winks at COVISHIELD & COVAXIN
India’s Comptroller General of Medicines (DCGI) VG Somani announced on Sunday that vaccines from Serum Institue of India (Covishield) and Bharat Biotech (Covaxin) have been granted restricted use authorization in an emergency situation . Covishield – a recombinant chimpanzee adenovirus vector vaccine – has an efficacy of 70.42%, with preliminary safety and immunogenicity data from Phase II / III trials submitted to the SEC. 50 million doses have been stored.
Meanwhile, Covaxin – a vaccine against the Corona virus inactivated by a whole virion – 22,500 participants have been vaccinated in phase III trials and have been shown to be safe according to the data available to date. On Thursday, Bharat Biotech (BBL) said the company has completed recruiting 25,800 participants in its Phase 3 clinical trials. As reported by the ICMR, BBL has already administered 24,000 volunteers with the first injection of its vaccine and 5,000 were administered with the second dose – no adverse events were detected. 20 million doses have been stored and phase 3 trials of the two vaccines are underway.
MP CM clarifies death of man 10 days after COVAXIN trial, calling it ‘misunderstanding’
COVAXIN completes recruitment of 25,800 volunteers for phase 3 trials ahead of “ dry run ”
[ad_2]
Source link